STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Results from the Phase III EMBARK trial show that in combination with leuprolide, Xtandi (enzalutamide) demonstrated a ...

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

The study demonstrated that XTANDI, in combination with androgen deprivation therapy (ADT), reduces the risk of death by 30% in men with metastatic hormone-sensitive prostate cancer.

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.